Syndrome |
Features |
SSc + PM (scleromyositis) |
Serologic marker: Positive anti-PM/Scl antibodies in 24% of patients (nucleolar staining on immunofluorescence) Clinical manifestations similar to antisynthetase syndrome; however, myositis and interstitial pneumonia are less frequent, the course is less severe, and the response to treatment is better |
SLE + scleroderma |
SLE with antibodies to histones and centromere: More frequent pulmonary, renal, and cardiac involvement SLE with anti-Scl-70 antibodies: Higher disease activity, more frequent pulmonary hypertension and renal involvement SLE with Raynaud phenomenon: More frequent anti-U1 RNP antibodies, dilated nail-fold capillaroscopy with “drop-outs” (typical for scleroderma) |
SLE + RA (rhupus) |
Destructive arthritis, rheumatoid nodules, positive RF and/or ACPAs; these most frequently precede features of SLE: leukopenia, thrombocytopenia, positive ANAs and anti-dsDNA, decreased levels of complement components |
ACPA, anti-citrullinated protein antibody; dsDNA, double-stranded DNA; PM, polymyositis; RA, rheumatoid arthritis; RF, rheumatoid factor; RNP, ribonucleoprotein; SLE, systemic lupus erythematosus; SSc, systemic sclerosis. |